REFERENCES
1. Mateos MV. How to maintain patients on long-term therapy:
understanding the profile and kinetics of adverse events. Leuk
Res . 2012;36 Suppl 1:S35-43. doi:10.1016/S0145-2126(12)70007-3
2. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC.
Understanding multiple myeloma pathogenesis in the bone marrow to
identify new therapeutic targets. Nature Reviews Cancer .
2007;7(8):585-598. doi:10.1038/nrc2189
3. Ogmundsdóttir HM, Haraldsdóttir V, M Jóhannesson G, et al. Monoclonal
gammopathy in Iceland: a population-based registry and follow-up.Br J Haematol . 2002;118(1):166-173.
doi:10.1046/j.1365-2141.2002.03589.x
4. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal
gammopathy of undetermined significance (MGUS) and subsequent multiple
myeloma among African American and white veterans in the United States.Blood . 2006;107(3):904-906. doi:10.1182/blood-2005-08-3449
5. Landgren O, Katzmann JA, Hsing AW, et al. Prevalence of monoclonal
gammopathy of undetermined significance among men in Ghana. Mayo
Clin Proc . 2007;82(12):1468-1473. doi:10.1016/S0025-6196(11)61089-6
6. Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of Monoclonal
Gammopathy of Undetermined Significance. New England Journal of
Medicine . 2006;354(13):1362-1369. doi:10.1056/nejmoa054494
7. Blessum C, Jeppsson JO, Aguzzi F, Bernon H, Bienvenu J. [Capillary
electrophoresis: principles and practice in clinical laboratory].Ann Biol Clin (Paris) . 1999;57(6):643-657.
8. Abdallah N, Rajkumar SV, Greipp P, et al. Cytogenetic abnormalities
in multiple myeloma: association with disease characteristics and
treatment response. Blood Cancer Journal 2020 10:8 .
2020;10(8):1-9. doi:10.1038/s41408-020-00348-5
9. Decaux O, Rodon P, Ruelland A, Estepa L, Leblay R, Grosbois B.
Épidémiologie descriptive des gammapathies monoclonales. Expérience d’un
centre hospitalier général et d’un service de médecine interne de centre
hospitalier et universitaire. Revue de Medecine Interne .
2007;28(10):670-676. doi:10.1016/j.revmed.2007.04.011
10. Katzmann JA, Kyle RA, Benson J, et al. Screening panels for
detection of monoclonal gammopathies. Clinical Chemistry .
2009;55(8):1517-1522. doi:10.1373/clinchem.2009.126664
11. Belouni R, Allam I, Cherguelaine K, et al. Epidemiological and
immunochemical parameters of monoclonal plasma cell dyscrasias of 2121
cases in Algeria. Current Research in Translational Medicine .
2020;68(2):67-70. doi:10.1016/j.retram.2019.11.003
12. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, et al. Gammapathies
monoclonales en Tunisie: Analyse épidé miologique, immunochimique et
étiologique d’une série de 288 cas. Pathologie Biologie .
2005;53(1):19-25. doi:10.1016/j.patbio.2004.01.014
13. R G, M D, L K, et al. Prevalence of Monoclonal Gammopathy of
Undetermined Significance in India-A Hospital-based Study.Clinical lymphoma, myeloma & leukemia . 2018;18(9):e345-e350.
doi:10.1016/J.CLML.2018.06.005
14. Dispenzieri A, Kyle RA, Lacy MQ, et al. POEMS syndrome: definitions
and long-term outcome. Blood . 2003;101(7):2496-2506.
doi:10.1182/blood-2002-07-2299
15. Singh G. Serum and Urine Protein Electrophoresis and Serum-Free
Light Chain Assays in the Diagnosis and Monitoring of Monoclonal
Gammopathies. The journal of applied laboratory medicine .
2020;5(6):1358-1371. doi:10.1093/JALM/JFAA153
16. O L, BI G, JA K, et al. Racial disparities in the prevalence of
monoclonal gammopathies: a population-based study of 12,482 persons from
the National Health and Nutritional Examination Survey. Leukemia .
2014;28(7):1537-1542. doi:10.1038/LEU.2014.34